Development of Paclitaxel Resistance in Triple-Negative Breast Cancer Is Associated with Extensive DNA Methylation Changes That Are Partially Reversed by Decitabine
Lenka Trnkova, Monika Buríková, Andrea Šoltýsová, Andrej Ficek, Jana Plavá, Andrea Čumová, Lucia Rojikova, Kristína Jakič, Eva Sedláčková, Boris Tichý, Vojtěch Bystrý, Florence Busato, Yimin Shen, Miroslava Matúšková, Lucia Kučerová, , Božena Smolková
This study shows that paclitaxel resistance in triple-negative breast cancer is linked to DNA methylation changes, which can be partially reversed by decitabine to enhance chemosensitivity.
Drug Resistance Updates · Jan 2, 2026Peer-reviewedCancer Biology